









Markets
/
Stocks
/
nasdaq-biib
/

Biogen Inc

BIIB

View Detailed Chart

130.070USD

+4.480+3.57%

Close 07/01, 16:00（ET）Quotes delayed by 15 min

19.06BMarket Cap

12.88P/E TTM



Biogen Inc

130.070

+4.480+3.57%

Company

Intraday

30m

Today

+3.57%

5 Days

+2.98%

1 Month

+0.22%

6 Months

-14.94%

Year to Date

-14.94%

1 Year

-43.88%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 37 analysts

BUY

Current Rating

170.218

Target Price

35.53%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

168

Total

Median

Average

Company name

Ratings

Analysts

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(3)

Neutral(4)

Buy(6)

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.786

Neutral

RSI(14)

54.733

Neutral

STOCH(KDJ)(9,3,3)

46.198

Buy

ATR(14)

3.487

Low Volatility

CCI(14)

43.456

Neutral

Williams %R

48.030

Neutral

TRIX(12,20)

-0.038

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

127.194

Buy

MA10

126.718

Buy

MA20

129.554

Buy

MA50

125.719

Buy

MA100

130.757

Sell

MA200

148.892

Sell

News

More news coming soon, stay tuned...

Company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Ticker SymbolBIIB

CompanyBiogen Inc

CEOMr. Christopher A. (Chris) Viehbacher

Websitehttps://www.biogen.com/